Vir Biotechnology VIR

Vir Biotechnology, Inc. · Nasdaq · Biological Products, (No Diagnostic Substances)

$8.39-5.41%close on Nov. 20, 2026 · volume 3.1M · Yahoo Finance

Price, last 64 sessions

$10.00$12.00Sept. 2026Oct. 2026Nov. 2026
Aug. 24, 2026 to Nov. 20, 2026 · high $13.65 · low $8.39 · SEC filing, placed when SEC released it

Our coverage

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
Nov. 3, 2026Vanina de Verneuil
EVP, General Counsel, Corp Sec
Sold
10b5-1 plan
2,407$11.10$26,718
Nov. 2, 2026Vanina de Verneuil
EVP, General Counsel, Corp Sec
Sold
10b5-1 plan
1,343$11.33$15,222

Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 24 →
  • 4Nov. 16, 2026, 12:16 p.m. ETView on SEC.gov
  • 4Nov. 16, 2026, 12:15 p.m. ETView on SEC.gov
  • 424B5Nov. 16, 2026, 9:18 a.m. ETView on SEC.gov
  • 8-KNov. 13, 2026, 9:47 p.m. ETView on SEC.gov

    Entry into a material definitive agreement · Other events · Financial statements and exhibits

    AI summary, unreviewedVir Biotechnology prices 15,000,000-share public offering at $10.00 per share for $150 million gross proceeds

  • 424B5Nov. 13, 2026, 9:41 p.m. ETView on SEC.gov
  • 424B5Nov. 12, 2026, 4:16 p.m. ETView on SEC.gov
  • SCHEDULE 13GNov. 10, 2026, 9:35 a.m. ETView on SEC.gov
  • 8-KNov. 9, 2026, 8:31 a.m. ETView on SEC.gov

    Regulation FD disclosure · Other events · Financial statements and exhibits

    AI summary, unreviewedVir Biotechnology Phase 3 ECLIPSE 1 Hits Primary Endpoint at 44% Response, Key Secondary at 79% Undetectable Virus